Poster Abstract Session:
146. Pneumococcal Vaccines
Friday, October 5, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID

Impact of Routine Pediatric PCV13 on the Incidence and Severity of Invasive Pneumococcal Disease in Adults in Ontario, Canada.
Sarah Nayani, PhD; Karen Green, MSc, RN; Hedan Han, MSc; Jeff Li, BSc; Agron Plevneshi, BSc; Wallis Rudnick, MSc.; Allison McGeer, MD, MSc
Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
Marie-Claude Breton, MPharm; Raymond Farkouh, PhD; Jelena Vojicic, MD; Michele Wilson, MSPH; Cheryl McDade, BA; Matt Wasserman, MSc
  • 2018 IDWEEK_Canada AMR Poster.pdf (1021.0 kB)
  • Emergence of Multidrug Resistant Serotype 24 among Children under 2 years old with Invasive Pneumococcal Disease after the Introduction of PCV13 in Argentina
    Paula Gagetti, MD; Alejandra Menocal, MD; Diego Faccone, PhD; Sofia Fossati, MD; Daniela Napoli, MD; Mabel Regueira, MD; Argentina Spn Working, Group; Alejandra Corso, MD
  • Gagetti ID Week 2018.pdf (1.0 MB)
  • Evolving impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease
    Inci Yildirim, MD PhD MSc; Brent A. Little, PhD; Kimberly M. Shea, PhD, MPH; Stephen I. Pelton, MD; Members Of The Department Of Public Health Massachusetts, MDPH
    County-Wide Pediatric IPD Experience Following Prevnar 13 Implementation
    Delma Nieves, MD; Stephanie Osborne, BS, RN; Michele Cheung, MD MPH; Antonio Arrieta, MD, FIDSA
  • 1432 Nieves ID Week 2018.pdf (553.1 kB)
  • The Cost-effectiveness of Vaccinating with an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
    Van Nguyen, Pharm.D.; Carla Vizzotti, MD; Analia Uruena, MD; Norberto Giglio, MD; Maria Cecilia Magneres, MD; Heather Richmond, MPH
    Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
    Olivia M. Almendares, MSPH; Wei Xing, MS; Monica M. Farley, MD, FIDSA; William Schaffner, MD, FIDSA, FSHEA; Ann Thomas, MD, MPH; Arthur Reingold, MD, FIDSA; Lee H. Harrison, MD; Corinne Holtzman, MPH; Jemma V. Rowlands, MPH; Susan Petit, MPH; Meghan Barnes, MSPH; Salina Torres, PhD; Bernard Beall, PhD; Cynthia Whitney, MD, MPH, FIDSA; Tamara Pilishvili, MPH, PhD
    Family Duty and Safety Linked to Overcoming Attitudinal Barriers to Adult Pneumococcal Vaccination in Disparate Populations
    Maria-Stephanie Tolg, PharmD; Marc Hutchison, Ph.D; Brian Krueger, Ph.D; Katherine Orr, PharmD; Jennifer DeAngelis, BA; Aisling Caffrey, PhD, MS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
    Potential Impact of Routine Use of 13-valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
    Jelena Vojicic, MD; Stephane Dion, PhD; Raúl E. Isturiz, MD; Craig Laferriere, PhD; Maria Major, MPH; Rajeev M. Nepal, PhD; Jose A. Suaya, MD, PhD; John M. McLaughlin, PhD
  • Impact PCV13 on Hosp.pdf (939.1 kB)
  • Doses of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM)
    Hsin-Yun Sun, MD; Aristine Cheng, MD; Shang-Yi Huang, M.D.; Sui-Yuan Chang, DSc; Yee-Chun Chen, M.D., Ph.D.; Shan-Chwen Chang, M.D., PhD
    Pneumonia Hospitalizations Averted with 13-valent Pneumococcal Conjugate Vaccination of Adults Aged 18-64 Years with Diabetes in The United States
    Jose Suaya, MD, PhD; Bradford D. Gessner, MD; Erica Chilson, PharmD; Jelena Vojicic, MD; David L. Swerdlow, MD; Raúl E. Isturiz, MD; John M. McLaughlin, PhD
  • IDWeerk_diabetes_2018v10f.pdf (125.2 kB)
  • Serotypes 8 and 3 are the leading cause of invasive pneumococcal disease in adults in Portugal (2015-2017)
    Catarina Silva-Costa, PhD; Elísia Lopes, MSc; Mario Ramirez, PhD; Jose Melo-Cristino, MD, PhD
    Trends in Antimicrobial Non-susceptibility of PCV13-type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017
    Rodrigo E. Mendes, Ph.D.; Jose A. Suaya, MD, PhD; Timothy B. Doyle, MS; Leah N. Woosley, B.S.; Robert K. Flamm, PhD; Bradford D. Gessner, MD; Raul E. Isturiz, MD
    Impact of 10-valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns among Children Aged <5 Years and Adults with HIV Infection, Kenya 2009–2013
    Miwako Kobayashi, MD, MPH; Lindsay Kim, MD, MPH; Godfrey Bigogo, MPH; Daniel Ondari, BA, CM; Laura Conklin, MD; Arthur Odoyo, BS; Herine Odiembo, MPH; Fabiana Pimenta, PhD; Dominic Ouma, MPH; Aaron Harris, MD, MPH; Kennedy Odero, MA; Jennifer Milucky, MPH; Alice Ouma, MSc; George Aol, MPH; Allan Audi, MSc; Clayton Onyango, MSc; Leonard Cosmas, MPH; Geofrey Jagero, MSc; Jennifer Farrar, MPH; Maria Da Gloria Carvalho, PhD; Cynthia Whitney, MD, MPH, FIDSA; Robert F. Breiman, MD, FIDSA; Fernanda C. Lessa, MD, MPH
    Correlation between Adult Invasive and Non-Invasive Streptococcus pneumoniae Disease in 13-valent Pneumococcal Conjugate Vaccine Serotypes in the United States
    Jose A. Suaya, MD, PhD; Adriano G. Arguedas, MD; Rodrigo E. Mendes, Ph.D.; Jelena Vojicic, MD; David L. Swerdlow, MD; Raul E. Isturiz, MD; Bradford D. Gessner, MD
  • IDWeerk_correlation_2018v8.pdf (137.4 kB)
  • CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.